EP0091241B1 - Kondensierte Pyrrolinon-Derivate, und ihre Herstellung - Google Patents

Kondensierte Pyrrolinon-Derivate, und ihre Herstellung Download PDF

Info

Publication number
EP0091241B1
EP0091241B1 EP83301656A EP83301656A EP0091241B1 EP 0091241 B1 EP0091241 B1 EP 0091241B1 EP 83301656 A EP83301656 A EP 83301656A EP 83301656 A EP83301656 A EP 83301656A EP 0091241 B1 EP0091241 B1 EP 0091241B1
Authority
EP
European Patent Office
Prior art keywords
compound
alkyl
phenyl
chloro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP83301656A
Other languages
English (en)
French (fr)
Other versions
EP0091241A2 (de
EP0091241A3 (en
Inventor
Kentaro Hiraga
Yoshiaki Saji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP1982/000096 external-priority patent/WO1983003410A1/ja
Priority claimed from PCT/JP1982/000401 external-priority patent/WO1984001576A1/ja
Priority claimed from PCT/JP1983/000032 external-priority patent/WO1984003089A1/ja
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to AT83301656T priority Critical patent/ATE39483T1/de
Publication of EP0091241A2 publication Critical patent/EP0091241A2/de
Publication of EP0091241A3 publication Critical patent/EP0091241A3/en
Application granted granted Critical
Publication of EP0091241B1 publication Critical patent/EP0091241B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Definitions

  • This invention relates to novel condensed pyrrolinone derivatives of value as medicines and their production.
  • DE-B-2 141 634 which relates to isoindoline derivatives
  • DE-B-2 300 491 which relates to pyrrolo[3,4-b]pyrazine derivatives
  • US-A-4 124 711 which relates to dithiepino[1,4][2,3-C]pyrrole derivatives.
  • the compounds of these prior art references are tranquilizers and anti-convulsant agents.
  • This invention provides a compound of the formula (I) wherein
  • ring A may optionally be substituted by one or 2 substituents just mentioned above.
  • substituents include chlorine, bromine, fluorine and iodine, preferably chlorine;
  • C 2-5 alkanoylamino includes e.g. acetylamino, propionylamino and butyrylamino;
  • C 2 - 5 alkoxycarbonyl includes e.g. methoxycarbonyl, ethoxycarbonyl, and propoxycarbonyl.
  • substituents may be on any position of the ring A.
  • the substituent(s) preferably is at the 5- and/or 6-position of the ring as isoindolinone.
  • the cyclic group X may for example be an aryl (e.g. phenyl or naphthyl), or is pyridyl, quinolyl or naphthyridinyl.
  • Such cyclic group may optionally have 1 to 3 substituents, selected from halogen (e.g. Cl, Br, F, I), C 1-4 alkyl (e.g. methyl, ethyl, propyl, butyl, isobutyl), Ci- 4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy), methylenedioxy, phenoxy, benzyloxy, hydroxyl, C 2 - 5 alkanoyloxy (e.g.
  • acetoxy, propionyloxy, butyryloxy amino, di-C 1-4 alkylamino (e.g. dimethylamino, diethylamino, dipropylamino, dibutylamino), ⁇ -hydroxy-C 1-3 alkyl (e.g. hydroxymethyl, hydroxyethyl), C 2 - 5 alkanoyl (e.g. acetyl, propionyl, butyryl), benzoyl, amido, nitro, cyano, trifluoromethyl, C 1-4 alkythio (e.g.
  • C 2 - 5 alkanoyloxy-C 1-4 alkyl e.g. acetyloxyethyl, propionyloxymethyl
  • C 2-5 alkanoylamino e.g. acetylamino, propionylamino
  • methoxycarbonyl and ethoxycarbonyl ethoxycarbonyl.
  • the above-mentioned cyclic group is preferably unsubstituted or substituted with one halogen atom or C 1-4 alkoxy group.
  • R 2 and R 3 may, together with the adjacent N atom, form a 5- to 7-membered cyclic amino group which may include N, 0 or S as a second hetero-atom, in addition to the above N atom.
  • cyclic amino groups having one N atom are pyrrolidinyl, piperidino and hexahydroazepinyl or those having two N atoms, one N and one S atoms, or one N and one 0 atoms such as piperazinyl, morpholino and thiazolidinyl.
  • Each of these cyclic amino groups may have 1 to 2 substituents selected from hydroxyl, C 1-4 alkoxy (e.g.
  • methoxy, ethoxy, propoxy, isopropoxy C 1-4 alkyl (e.g. methyl, ethyl, propyl, isopropyl), C 2-5 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl), phenyl-C 1-4 alkyl (e.g. benzyl, phenethyl, a-methylbenzyl), phenyl, piperidino and pyridyl.
  • C 1-4 alkyl e.g. methyl, ethyl, propyl, isopropyl
  • C 2-5 alkoxycarbonyl e.g. methoxycarbonyl, ethoxycarbonyl
  • phenyl-C 1-4 alkyl e.g. benzyl, phenethyl, a-methylbenzyl
  • phenyl piperidino and pyridyl.
  • the compounds of formula (I) of this invention can be produced, for example by hydrolyzing a compound of the formula (II) wherein each symbol is as defined hereinbefore; Q is ⁇ COOR 4 (R 3 is a lower alkyl group) or -CN, and, if necessary, esterifying or amidating the hydrolysate compound.
  • the starting compound of general formula (III) can be produced in accordance with the process described in J. Org. Chem. 26,2273 (1961) or by the process described in J. Org. Chem. 26,2273 (1961) from a compound of general formula (III') which can be prepared by or in general accordance with the processes described in Japanese Patent Publication No. 11940/1973, Japanese Published and Unexamined Patent No. 100495/1977 (Kokai Sho-52-100495), Helv. Chim. Acta 52, 2228 (1965), J. Hetelocycl. Chem. 7, 1121 (1970), and Chem. Ber. 40, 4850 (1907). wherein each symbol is as defined hereinbefore.
  • a compound of general formula (III) is dissolved in a lower alkanol (R°OH) and the solution is heated together with a catalyst amount of concentrated hydrochloric acid, whereby the alkyl ether (IV) is easily obtained.
  • the ether compound (IV) can be easily converted to a compound (V) by the reaction of (IV) with a malonic acid diester (e.g. dimethyl malonate, diethyl malonate) under the ordinary conditions of Friedel-Crafts reaction, for example in dichloromethane or dichloroethane solvent in the presence of aluminum chloride.
  • a malonic acid diester e.g. dimethyl malonate, diethyl malonate
  • the catalyst may be an inorganic acid such as sulfuric acid, hydrochloric acid, an organic acid or an anhydride thereof such as paratoluenesulfonic acid, trifluoroacetic anhydride, trifluoromethanesulfonic anhydride, or a salt of a heavy metal such as tin, cobalt, iron, aluminum etc. (e.g. BuSnO 2 H, Bu 2 SnO).
  • said reactive derivative of (1-1) there may be mentioned the acid halides (e.g. acid chloride, acid bromide), the acid anhydride obtained by elimination of one molecule of water from 2 molecules of (1-1), and the mixed acid anhydrides obtainable by replacing the carboxyl hydrogen of (1-1) with ethoxycarbonyl, isobutyloxycarbonyl, benzyloxycarbonyl, etc.
  • the reaction of such a reactive derivative with alcohol (X) can be generally conducted in a solvent that does not interfere with the reaction, such as ether, benzene, tetrahydrofuran, dichloromethane, chloroform, dimethylformamide.
  • this reaction is conducted in the presence of a base such as pyridine, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, triethylenediamine, and the reaction temperature is -10° to +100°C and, preferably, 0° to 30°C.
  • a base such as pyridine, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, triethylenediamine
  • the compound (1-2) can also be produced by reacting an alkali metal salt (e.g. sodium salt) or silver salt of (1-1) with a halide of formula (XI) wherein R' is as defined hereinbefore; B is a halogen atom.
  • an alkali metal salt e.g. sodium salt
  • the compound (1-2) wherein R' is a tert-butyl group can also be produced by adding (1-1) to isobutylene. This reaction is conducted in the presence of an acid catalyst such as sulfuric acid, boron trifluoride, etc.
  • an acid catalyst such as sulfuric acid, boron trifluoride, etc.
  • the reaction is carried out either in a solvent such as toluene, xylene, dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, dimethylformamide or in no solvent.
  • a solvent such as toluene, xylene, dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, dimethylformamide or in no solvent.
  • the reaction may be conducted in the presence of a base such as pyridine, picoline, triethylamine, 4-dimethylaminopyridine, potassium carbonate, sodium carbonate, an acid such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, or an alkali metal salt such as lithium chloride, sodium chloride, sodium iodide, lithium iodide, lithium bromide, sodium bromide.
  • a base such as pyridine, picoline, triethylamine, 4-dimethylaminopyridine, potassium carbonate, sodium carbonate, an acid such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, or an alkali metal salt such as lithium chloride, sodium chloride, sodium iodide, lithium iodide, lithium bromide, sodium bromide.
  • the reaction is normally carried out at a temperature of 0
  • the reactive derivative of the carboxyl group of said compound (1-1) includes, in addition to those employed in the above-mentioned process (2), such other derivatives as N-hydroxydiacylimide esters (e.g. N-hydroxysuccinimide ester, N-hydroxyphthalimide ester, N-hydroxy-5-norbornene-2,3-dicarboximide ester), for instance.
  • N-hydroxydiacylimide esters e.g. N-hydroxysuccinimide ester, N-hydroxyphthalimide ester, N-hydroxy-5-norbornene-2,3-dicarboximide ester
  • This reaction is generally conducted in a solvent such as dichloromethane, tetrahydrofuran, chloroform, dimethylformamide, acetonitrile. These solvents are mentioned only as examples and any other solvent that does not interfere with the reaction can be successfully employed.
  • this reaction can be conducted in the presence of a base such as pyridine, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, triethylenediamine, potassium carbonate, sodium hydroxide.
  • a base such as pyridine, triethylamine, 4-dimethylaminopyridine, diisopropylethylamine, triethylenediamine, potassium carbonate, sodium hydroxide.
  • the reaction temperature is generally -10°C to +100°C, and preferably 0°C to 30°C.
  • a dehydrating agent such as a dicyclohexylcarbodiimide, carbonyldiimidazole, diethyl phosphorocyanidate, diphenylphosphoryl azide.
  • the reaction may also be conducted in the presence of a base such as pyridine, picoline, triethylamine, sodium hydroxide, potassium carbonate.
  • a base such as pyridine, picoline, triethylamine, sodium hydroxide, potassium carbonate.
  • the reaction is generally conducted at a temperature of -20°C to +150°C. In most instances, the reaction proceeds satisfactorily at room temperature.
  • the compound (I) can also be produced in one step by reacting said compound (III) with a compound of formula (XIII)
  • This reaction is conducted in an organic solvent such as toluene, ethyl acetate, methoxyethane.
  • any other organic solvent that does not interfere with the reaction can also be employed.
  • the reaction temperature is generally 10°C to 120°C.
  • the amide (1-3) can be produced by the treatment of the ester (1-2) with the amine (XII) described above under the noted reaction conditions. If necessary, it is first hydrolyzed to the free carboxyl group. It is then converted to a reactive derivative such as an acid chloride or a mixed acid anhydride and reacted with the amine mentioned above.
  • the compound of formula (XIII-2) wherein R' is as defined hereinbefore is a known compound and can be prepared for example by the process described in Helv. Chim. Acta. 44, 1242 (1957).
  • the compound of formula (XIII-3) wherein R 2 and R 3 are as defined hereinbefore is a novel compound and can be produced for example by the steps of treating an a-haloacetamide compound of formula (XIV) wherein B' is a halogen atom; and R 2 and R 3 are as defined hereinbefore and triphenylphosphine in the known manner, for example by heating them together at 10 to 120°C in toluene, benzene, ethyl acetate, acetonitrile, dimethylformamide or the like and treating the resulting phosphonium salt (XV) wherein B', R 2 and R 3 are as defined hereinbefore in the known manner, for example by reacting (XV) with an alkali, e.g. sodium hydroxide or potassium hydroxide, in aqueous solution at 0 to 50°C.
  • an alkali e.g. sodium hydroxide or potassium hydroxide
  • the compounds (I) of this invention which can be produced by the above-described reactions, i.e. compounds (1-1), (1-2) and (1-3), can each be isolated from the reaction mixture by separation and purification procedures known per se (e.g. extraction, recrystallization, column chromatography).
  • the compound (1-1) wherein Y is a free carboxyl group can be isolated in the form of a salt, for example as a metal salt such as the sodium, potassium or calcium salt.
  • a salt for example as a metal salt such as the sodium, potassium or calcium salt.
  • the compound (I) of this invention when the compound (I) of this invention is basic, it can be isolated in the form of a salt with an acid, examples of which are pharmaceutically acceptable salts such as salts with inorganic acids (e.g. hydrochloride, nitrate, phosphate, hydrobromide) or salts with organic acids (e.g. acetate, fumarate, maleate, oxalate, tartarate, methanesulfonate, etc.).
  • inorganic acids e.g. hydrochloride, nitrate, phosphate, hydrobromide
  • organic acids e.g. acetate, fumarate, maleate, oxalate, tartarate, methanesul
  • the compound (I) according to this invention acts on the central nervous system to display a strong antianxiety effect as demonstrated by anticonflict tests in rats.
  • the minimal lethal dose (MLD) of the compound of this invention is at least 500 mg/kg in mice and the minimal effective dose (MED) is not more than 2.5 mg/kg in rats. Since the safety margin of the compound is very large and its hypnotic and muscle relaxing effects as side effects are very weak as compared with the benzodiazepine antianxiety drugs currently on the market, it can be administered safely and effectively as an antianxiety drug to mammalian animals including human beings.
  • the indications of this compound may include various psychosomatic diseases such as autonomic imbalance, nervous vomiting, neurodermatitis, alopecia areata, nervous angina, nervous dyspnea, etc. as well as anxiety neurosis, and the compound (I) can be used for the prevention or treatment of such diseases. Furthermore, this compound has anticonvulsant activity and, therefore, can be used in cases of epilepsy, traumatic convulsion, etc.
  • the compound according to this invention can be administered orally or otherwise to mammalian animals including man, in various dosage forms such as tablets, granules, capsules, injections, suppositories, etc.
  • the compound is administered generally in the daily dose of 0.001 to 50 mg per kg body weight in the case of animals and in the daily dose of 0.1 to 100 mg, or preferably 0.5 to 20 mg, in the case of an adult human.
  • the pharmacological properties of the compounds (I) of this invention were investigated by determining the substituting power thereof for radioactive diazepam from a benzodiazepine receptor.
  • N-(4-methoxyphenyl)-4-nitrophthalamide (12 g) was suspended in a mixture of methanol (80 ml) and tetrahydrofuran (80 ml) and, under ice-cooling and stirring, sodium borohydride (1.6 g) was added. Water (300 ml) was added to the mixture and crude crystals were collected by filtration to give a mixture (11 g) of 3-hydroxy-2-(4-methoxyphenyl)-5-nitroisoindolin-1-one and 3-hydroxy-2-(4-methoxyphenyl)-6-nitroiso- indolin-1-one.
  • the mother liquor obtained above was concentrated and the residue was subject to purification by column chromatography on silica gel and eluted with toluene-ethyl acetate.
  • 6-chloro-2-(7-chloro-1,8-naphthyridin-2-yl)-3-piperidinocarbonyl- methylisoindolin-1-one was obtained from 6-chloro-3-hydroxy-2-(7-chloro-1,8-naphthyridin-2-yl)isoindolin-l-one.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (15)

1. Verbindung der Formel (I)
Figure imgb0089
worin
X gegebenenfalls durch 1 bis 3 Substituenten ausgewählt aus Halogen, C1-4 Alkyl, C1-4 Alkoxy, Methylendioxy, Phenoxy, Benzyloxy, Hydroxyl, C2-5 Alkanoyloxy, Amino, Di-C1-4 Alkylamino, ω-Hydroxy-Ci-3 Alkyl, C2-5 Alkanoyl, Benzoyl, Amino, Nitro, Cyano, Trifluormethyl, Cl-4 Alkylthio, C2-5 Alkanoyloxy-C1-3 Alkyl, C2-5 Alkanoylamino, Methoxycarbonyl oder Äthoxycarbonyl substituiertes Aryl, Naphthyridinyl, Pyridyl oder Chinolyl ist;
Y die Carboxylgruppe ―COOR1 darstellt, worin R1 für C1-4 Alkyl, Phenyl-C1-4 Alkyl oder Phenyl steht oder
Figure imgb0090
bedeutet, worin R2 und R3 gleich oder verschieden sind und jeweils Wasserstoff, Cl-4 Alkyl, Phenyl-C1-4 Alkyl, Phenyl, Thiazolyl oder Benzothiazolyl darstellen und R2 und R3 jeweils durch Halogen, Hydroxy, C1-4 Alkoxy, C2-5 Alkoxycarbonyl oder Di-C1-4 Alkylamino substituiert sein können und
R2 und R3 zusammen mit dem angrenzenden N-Atom eine 5- bis 7-gliedrige cyclische Aminogruppe bilden können, die ein N-, O- oder S-Atom als zweites Heteroatom zusätzlich zu dem genannten angrenzenden N-Atom enthalten kann und die 1 bis 2 Substituenten ausgewählt aus Hydroxyl, C1-4 Alkoxy, C1-4 Alkyl, C2-5 Alkoxycarbonyl, Phenyl-C1-4 Alkyl, Phenyl, Piperidino oder Pyridyl aufweisen kann;
Z für -CH=CH-CH=CH-; -S-(CH2)2-S-, -N=CHCH=N- oder -(CH2)4- steht; der Ring A gegebenenfalls durch 1 oder 2 Substituenten von Halogen, Nitro, Amino, C2-5 Alkanoylamino, C2-5 Alkoxycarbonyl, Carboxyl oder Carbamoyl aufweist; oder ein Salz derselben.
2. Verbindung nach Anspruch 1, worin X für gegebenenfalls durch Cl-4 Alkoxy oder Halogen substituiertes Phenyl oder Naphthyridinyl steht.
3. Verbindung nach Anspruch 1, worin Y -CO-NR2R3 darstellt.
4. Verbindung nach Anspruch 1, worin Z -CH=CH-CH=CH- ist.
5. Verbindung nach Anspruch 3, worin Y ein cyclisches Aminocarbonyl darstellt.
6. Verbindung nach Anspruch 1, worin X für ein durch C1-4 Alkoxy oder Halogen substituiertes Phenyl steht; Y ein cyclisches Aminocarbonyl bedeutet; Z -CH=CH-CH=CH- darstellt und der Ring A gegebenenfalls durch Halogen substituiert ist.
7. Verbindung nach Anspruch 1, worin die Verbindung 5-Chlor-2-(4-methoxyphenyl)-3-(4-methylpiperazin-1-yl)-carbonylmethylisoindolin-1-on ist.
8. Verbindung nach Anspruch 1, worin die Verbindung 2-(4-Methoxyphenyl)-3-piperidinocarbonyl- methylisoindolin-1-on ist.
9. Verbindung nach Anspruch 1, worin die Verbindung 5-Chlor-2-(4-methoxyphenyl)-3-piperidinocar- bonylmethylisoindolin-1-on ist.
10. Verbindung nach Anspruch 1, worin die Verbindung 5-Nitro-2-(4-methoxyphenyl)-3-piperidinocar- bonylmethylisoindolin-1-on ist.
11. Verbindung nach Anspruch 1, worin die Verbindung 5-Chlor-2-(7-chlor-1,8-naphthyridin-2-yl)-3-piperidinocarbonylmethylisoindolin-1-on ist.
12. Verbindung nach Anspruch 1, worin die Verbindung 6-Chlor-2-(7-chlor-1,8-naphthyridin-2-yl)-3-piperidinocarbonylmethylisoindolin-1-on ist.
13. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, oder eines Salzes derselben, das das Hydrolysieren einer Verbindung der Formel (II)
Figure imgb0091
worin jedes der Symbole die in Anspruch 1 angeführte Bedeutung besitzt, und Q für -COOR4 (R4 ist ein Niederalkyl) oder -CN steht und nach Bedarf Verestern oder Amidieren der erhaltenen Hydrolysatverbindung umfaßt.
14. Verfahren zur Herstellung einer Verbindung nach Anspruch 1, oder eines Salzes derselben, das die Umsetzung einer Verbindung der Formel (III)
Figure imgb0092
worin Z, X und A die in Anspruch 1 angeführte Bedeutung besitzen, mit einer Verbindung der Formel Ph3P=CHY umfaßt, worin Y die in Anspruch 1 angeführte Bedeutung besitzt.
15. Pharmazeutische Zusammensetzung, die (a) als Wirkstoff eine gegen Angstzustände wirksame Menge wenigstens einer der in Anspruch 1 definierten Verbindungen oder ein physiologisch verträgliches Salz derselben und (b) pharmazeutisch verträgliche Trägermittel hierfür enthält.
EP83301656A 1982-04-02 1983-03-24 Kondensierte Pyrrolinon-Derivate, und ihre Herstellung Expired EP0091241B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT83301656T ATE39483T1 (de) 1982-04-02 1983-03-24 Kondensierte pyrrolinon-derivate, und ihre herstellung.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/JP1982/000096 WO1983003410A1 (fr) 1982-04-02 1982-04-02 Derives d'isoindoline
WOPCT/JP82/00096 1982-04-02
WOPCT/JP82/00401 1982-10-07
PCT/JP1982/000401 WO1984001576A1 (fr) 1982-10-07 1982-10-07 Derives de pyrrolidone fondus
PCT/JP1983/000032 WO1984003089A1 (fr) 1983-02-05 1983-02-05 Derives condenses de pyrrolinone
WOPCT/JP83/00032 1983-02-05

Publications (3)

Publication Number Publication Date
EP0091241A2 EP0091241A2 (de) 1983-10-12
EP0091241A3 EP0091241A3 (en) 1984-07-11
EP0091241B1 true EP0091241B1 (de) 1988-12-28

Family

ID=27303767

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83301656A Expired EP0091241B1 (de) 1982-04-02 1983-03-24 Kondensierte Pyrrolinon-Derivate, und ihre Herstellung

Country Status (7)

Country Link
US (3) US4590189A (de)
EP (1) EP0091241B1 (de)
KR (1) KR900007780B1 (de)
AT (1) ATE39483T1 (de)
CA (1) CA1196330A (de)
DE (1) DE3378763D1 (de)
HK (1) HK104190A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104269C1 (ru) * 1989-11-23 1998-02-10 Рон-Пуленк Санте Производные изоиндолона или их соли с кислотами в качестве промежуточных соенинений для синтеза биологически активных соединений - пергидроизоиндолонов

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE39483T1 (de) * 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd Kondensierte pyrrolinon-derivate, und ihre herstellung.
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
US5264436A (en) * 1986-11-27 1993-11-23 Beecham Group P.L.C. Heterocyclic compounds which have useful pharmaceutical utility
FR2607503B1 (fr) * 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
US4959374A (en) * 1989-07-06 1990-09-25 Beecham Group P.L.C. Novel compounds
US5273978A (en) * 1991-07-10 1993-12-28 Takeda Chemical Industries, Ltd. Optically active isoindoline derivatives, their production and use
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
TR200101500T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
CN100548980C (zh) * 2002-11-26 2009-10-14 丸石制药株式会社 异吲哚啉衍生物
GB0308025D0 (en) * 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US20080021042A1 (en) * 2004-05-24 2008-01-24 Maruishi Pharmaceutical Co., Ltd. Composition For Controlling Neuropathic Pain
EP2271625B1 (de) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisochinoline, pharmazeutische zusammensetzungen damit und ihre therapeutische verwendung
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) * 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
EP3468545B1 (de) 2016-06-08 2026-08-05 President and Fellows of Harvard College Verfahren und zusammensetzungen zur verringerung von taktiler dysfunktion und angst im zusammenhang mit autismus-spektrum-störungen, rett-syndrom und fragilem x-syndrom
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (de) 2018-05-29 2022-01-19 President and Fellows of Harvard College Zusammensetzungen und verfahren zur verminderung von taktiler dysfunktion, angst und sozialer beeinträchtigung
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN117263909A (zh) * 2023-09-21 2023-12-22 常州大学 一种由亚砜叶立德制备异吲哚啉-1-酮的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957872A (en) * 1957-10-21 1960-10-25 Ciba Pharm Prod Inc Phthalimidines and process for manufacturing same
US3579524A (en) * 1968-06-05 1971-05-18 Miles Lab 2-aminoalkyl derivatives of phthalimidines
FR2101081B1 (de) * 1970-08-19 1974-01-11 Rhone Poulenc Sa
FR2117740B1 (de) * 1970-12-14 1974-04-12 Rhone Poulenc Sa
BE790408A (fr) * 1971-10-22 1973-04-20 Rhone Poulenc Sa Nouveaux derives de la pyrrolo (3,4-b) pyridine, leur preparation et les compositions medicinales qui les
OA04285A (fr) * 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
AR203996A1 (es) * 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
US4016274A (en) * 1973-05-15 1977-04-05 Rhone-Poulenc S.A. Naphthyridine derivatives
US4038391A (en) * 1973-05-15 1977-07-26 Rhone-Poulenc S.A. 6-(1,8-Naphthyridin-2-yl)-5-piperazino carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo-[3,4-b]pyrazines and related pyridines
US4164404A (en) * 1973-06-25 1979-08-14 American Cyanamid Company Dithiindicarboximide, dithiolanedicarboximide, thiapyrandicarboximide and pyrandicarboximide derivatives as plant growth regulants
JPS5046830A (de) * 1973-08-28 1975-04-25
CA1072557A (fr) * 1976-02-20 1980-02-26 Rhone-Poulenc Industries Derives du dithiepinno (1,4)(2,3-c) pyrrole, leur preparation et les compositions qui les contiennent
FR2451380A1 (fr) * 1979-03-15 1980-10-10 Rhone Poulenc Ind Nouveaux derives du dithiepinno (1,4) (2,3-c) pyrrole, leur preparation et les medicaments qui les contiennent
US4355031A (en) * 1981-05-11 1982-10-19 American Home Products Corp. 2,3-Dihydro-3-[4-(substituted)-1-piperazinyl]-1H-isoindol-1-ones
ATE39483T1 (de) * 1982-04-02 1989-01-15 Takeda Chemical Industries Ltd Kondensierte pyrrolinon-derivate, und ihre herstellung.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104269C1 (ru) * 1989-11-23 1998-02-10 Рон-Пуленк Санте Производные изоиндолона или их соли с кислотами в качестве промежуточных соенинений для синтеза биологически активных соединений - пергидроизоиндолонов

Also Published As

Publication number Publication date
US4788191A (en) 1988-11-29
HK104190A (en) 1990-12-21
US4590189A (en) 1986-05-20
CA1196330A (en) 1985-11-05
KR900007780B1 (ko) 1990-10-20
US4879293A (en) 1989-11-07
EP0091241A2 (de) 1983-10-12
EP0091241A3 (en) 1984-07-11
ATE39483T1 (de) 1989-01-15
KR840004405A (ko) 1984-10-15
DE3378763D1 (en) 1989-02-02

Similar Documents

Publication Publication Date Title
US4788191A (en) 1,3-dithiolano-, 1,4-dithiino- and 1,4-dithiepino[2,3-C]pyrrole derivatives, their production and use
US5231101A (en) Benzo[5,6]cyclohepta[1,2-B]pyridine derivatives and antiallergic agents comprising same
KR960003614B1 (ko) 1,2,3,3a,8,8a-헥사하이드로-3a,8(및 1,3a,8)-디(및 트리)메틸피롤로[2,3-b]인돌, 이를 함유하는 약제학적 조성물 및 이의 제조방법
DE69524114T2 (de) Naphthyridinonderivate
AU668694B2 (en) Saccharin derivative proteolytic enzyme inhibitors
CS254992B2 (en) Method of thieno-triazolo-1,4-diazepino-2-carboxyl acids' new amides production
FR2523582A1 (fr) Nouvelles 1h-pyrazolo(1,5-a)pyrimidines substituees, utiles notamment comme medicaments anti-inflammatoires et analgesiques, et procede pour leur preparation
EP0586560A1 (de) Neue benzopyrido-piperidyliden verbindungen, zusammensetzungen, verfahren zur herstellung und verwendung
US4778801A (en) Isoindolinone derivatives, production and use thereof
JPH0377885A (ja) ２―オキソ―１―オキサ―８―アザスピロ〔４，５〕デカン誘導体、それを含む医薬組成物及びその製造方法
US4409234A (en) Pyrazoloindazole derivatives and bronchodilating composition
JPH0967367A (ja) チオピラン誘導体
LU82419A1 (fr) Pyrido(1,2-a)pyrimidines substituees
US4356186A (en) Acetic acid derivatives and composition containing the same
US5075317A (en) Spirofurane derivatives
IE55377B1 (en) 1,5-diphenylpyrazolin-3-one compounds,method for preparing them,and pharmaceutical compositions containing these compounds
SU1382400A3 (ru) Способ получени конденсированных производных пирролинона или их гидрохлоридов
US4988822A (en) Intermediates for preparing 5-aroyl-1,2-dihydro-3H-pyrrolo(1,2-A)pyrrole-1,1-dicarboxylates
US4290954A (en) Tetrahydroxanthone derivatives
US4169899A (en) Penicillamine compounds
US3629251A (en) Derivatives of 9-aminoalkyl-1 2 8 9-tetraazaphenalenes
US4044134A (en) Fused pyrimidin-4(3H)-ones as antiallergy agents
DK161311B (da) Analogifremgangsmaade til fremstilling af 2-substituerede 3-karboxyalkyl-4,5-kondenserede pyrrolin-1-onderivater eller salte deraf
US4128648A (en) Substituted pyrano[4,3-d]-thiazolo[3,2-a]pyrimidines
US4436662A (en) Pyrrolo[3,4-d][2]benzazepinones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19841115

17Q First examination report despatched

Effective date: 19860121

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 39483

Country of ref document: AT

Date of ref document: 19890115

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3378763

Country of ref document: DE

Date of ref document: 19890202

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: TAKEDA CHEMICAL INDUSTRIES, LTD.

26N No opposition filed
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19950119

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19950120

Year of fee payment: 13

EAL Se: european patent in force in sweden

Ref document number: 83301656.1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950201

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19950216

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950224

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19950302

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19950315

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19950331

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19950412

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960324

Ref country code: GB

Effective date: 19960324

Ref country code: AT

Effective date: 19960324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960331

Ref country code: CH

Effective date: 19960331

Ref country code: BE

Effective date: 19960331

BERE Be: lapsed

Owner name: TAKEDA CHEMICAL INDUSTRIES LTD.

Effective date: 19960331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19961001

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19960324

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19961129

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19961001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19961203

EUG Se: european patent has lapsed

Ref document number: 83301656.1

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST